These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

542 related items for PubMed ID: 35534752

  • 1. Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women.
    Gupta N, Gupta D, Dixit J, Mehra N, Singh A, Krishnamurthy MN, Jyani G, Rajsekhar K, Kalaiyarasi JP, Roy PS, Malik PS, Mathew A, Malhotra P, Gupta S, Kumar L, Kataki A, Prinja S.
    Appl Health Econ Health Policy; 2022 Jul; 20(4):609-621. PubMed ID: 35534752
    [Abstract] [Full Text] [Related]

  • 2. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
    Mistry R, May JR, Suri G, Young K, Brixner D, Oderda G, Biskupiak J, Tang D, Bhattacharyya S, Mishra D, Bhattacharyya D, Dalal AA.
    J Manag Care Spec Pharm; 2018 Jun; 24(6):514-523. PubMed ID: 29799329
    [Abstract] [Full Text] [Related]

  • 3. Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective.
    Stellato D, Thabane ME, Park J, Chandiwana D, Delea TE.
    Pharmacoeconomics; 2021 Sep; 39(9):1045-1058. PubMed ID: 34105083
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer.
    Mayer EL, Ren Y, Wagle N, Mahtani R, Ma C, DeMichele A, Cristofanilli M, Meisel J, Miller KD, Abdou Y, Riley EC, Qamar R, Sharma P, Reid S, Sinclair N, Faggen M, Block CC, Ko N, Partridge AH, Chen WY, DeMeo M, Attaya V, Okpoebo A, Alberti J, Liu Y, Gauthier E, Burstein HJ, Regan MM, Tolaney SM.
    J Clin Oncol; 2024 Jun 10; 42(17):2050-2060. PubMed ID: 38513188
    [Abstract] [Full Text] [Related]

  • 9. Is adding ribociclib to fulvestrant cost-effective in treating postmenopausal women with HR+/HER2- advanced or metastatic breast cancer? A US payer perspective cost utility analysis.
    Berrios K, Burum A, Jeong E, Zhong L.
    J Manag Care Spec Pharm; 2022 Nov 10; 28(11):1282-1291. PubMed ID: 36282933
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2- advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2.
    Cameron D, Kumar Sharma V, Biswas C, Clarke C, Chandiwana D, Pathak P.
    J Med Econ; 2023 Nov 10; 26(1):357-365. PubMed ID: 36797664
    [Abstract] [Full Text] [Related]

  • 11. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
    Eggersmann TK, Degenhardt T, Gluz O, Wuerstlein R, Harbeck N.
    BioDrugs; 2019 Apr 10; 33(2):125-135. PubMed ID: 30847853
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. CDK4/6 inhibitors and endocrine therapy in the treatment of metastatic breast cancer: A real-world and propensity score-adjusted comparison.
    Coutinho-Almeida J, Silva AS, Redondo P, Rodrigues PP, Ferreira A.
    Cancer Treat Res Commun; 2024 Apr 10; 40():100818. PubMed ID: 38761788
    [Abstract] [Full Text] [Related]

  • 14. Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study.
    Martín M, Zielinski C, Ruiz-Borrego M, Carrasco E, Ciruelos EM, Muñoz M, Bermejo B, Margelí M, Csöszi T, Antón A, Turner N, Casas MI, Morales S, Alba E, Calvo L, de la Haba-Rodríguez J, Ramos M, Murillo L, Santaballa A, Alonso-Romero JL, Sánchez-Rovira P, Corsaro M, Huang X, Thallinger C, Kahan Z, Gil-Gil M.
    Eur J Cancer; 2022 Jun 10; 168():12-24. PubMed ID: 35429901
    [Abstract] [Full Text] [Related]

  • 15. Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR+/HER2- Metastatic Breast Cancer From the US and Chinese Perspectives.
    Zhang Y, Zeng X, Deng H, Ma F, Peng Y, Yi L, Tan C, Peng L.
    Clin Ther; 2019 Jun 10; 41(6):1175-1185. PubMed ID: 31104762
    [Abstract] [Full Text] [Related]

  • 16. Cost-Effectiveness of Adjuvant Abemaciclib and Ribociclib in High-Risk Hormone Receptor-Positive Early Breast Cancer: An Indian Perspective.
    Sra MS, Sasi A, Batra A, Bakhshi S, Ganguly S.
    JCO Glob Oncol; 2024 Jul 10; 10():e2300433. PubMed ID: 39024528
    [Abstract] [Full Text] [Related]

  • 17. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
    Bilgin B, Sendur MAN, Şener Dede D, Akıncı MB, Yalçın B.
    Curr Med Res Opin; 2017 Sep 10; 33(9):1559-1569. PubMed ID: 28657360
    [Abstract] [Full Text] [Related]

  • 18. Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer.
    Wilson FR, Varu A, Mitra D, Cameron C, Iyer S.
    Breast Cancer Res Treat; 2017 Nov 10; 166(1):167-177. PubMed ID: 28752187
    [Abstract] [Full Text] [Related]

  • 19. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
    Cersosimo RJ.
    Am J Health Syst Pharm; 2019 Aug 01; 76(16):1183-1202. PubMed ID: 31369120
    [Abstract] [Full Text] [Related]

  • 20. Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand.
    Dajsakdipon T, Susiriwatananont T, Wongkraisri C, Ithimakin S, Parinyanitikul N, Supavavej A, Dechaphunkul A, Sunpaweravong P, Neesanun S, Akewanlop C, Dejthevaporn T, TSCO Breast Oncology Group.
    BMC Cancer; 2024 Aug 16; 24(1):1018. PubMed ID: 39152401
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.